medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2006, Number 3

<< Back Next >>

Acta Med 2006; 4 (3)

Diagnosis and management of malignant pleural effusion

Salazar LMA, Martínez MD

Language: Spanish
References: 45
Page: 175-181
PDF size: 58.82 Kb.


ABSTRACT

Malignant pleural effusion is a clinical problem in patients with neoplasic disease. These may be the first manifestation of cancer, therefore, an important source to the diagnosis, and a cause of death and poor survival. Due to the prognosis the corner stone of treatment is to relieve the dyspnea. However, the management remains controversial. Pleural effusions secondary a neoplasic disease has been classified in malignant when malignant cells are found in the pleural fluid and paramalignant when they are absent. Malignant pleural effusion in lung cancer usually excludes the possibility of surgery, and the treatment might be evaluated according to the generals conditions of the patient, symptoms and the expecting survival. Chemical pleurodesis is the more accepted palliative therapy for patients with recurrent, symptomatic malignant pleural effusions. Adequate assessment of the efficacy of specific chemical agents has been problematic; however, talc is the most effective sclerosant available for pleurodesis.


REFERENCES

  1. Salazar-Lezama MA. El diagnóstico de la patología pleural. Neumología y Cirugía de Tórax 1996; 55: 55-66.

  2. Sahn SA. The Pleura. Am Rev Respir Dis 1988; 138: 184-234.

  3. Turton CWG. Troublesome pleural fluid. Br J Dis Chest 1987; 87: 217-224.

  4. DeCamp MM, Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive disease of the pleura and pericardium. Chest 1997; 112: 291S-295S.

  5. Marel M, Stansky B, Melinová L, Svanvová E, Light RW. Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest 1995; 107: 1598-1603.

  6. Salazar-Lezama, García-López. Etiología del derrame pleural en el Instituto Nacional de Enfermedades Respiratorias. Rev Inst Nal Enf Resp Mex 1999; 12: 97-100.

  7. Light RW. Pleural Diseases. 2nd ed. Lea and Febiger: Philadelphia, 1990.

  8. Storey DD, Dines DE, Coles DT. Pleural Effusion. A diagnostic dilemma. JAMA 1976; 236: 2183-2186.

  9. Valdés L, Alvarez D, Valle JM, Pose A, San José E. The etiology of pleural effusions in an area with high incidence of tuberculosis. Chest 1996; 109: 158-62.

  10. Hott JW. Malignant pleural effusions. Seminars in respiratory and critical care medicine 1995; 16: 333-39.

  11. Lopez-Segundo E, Salazar-Lezama MA. Métodos diagnósticos en el derrame pleural maligno. Revision de casos de 1992-2000. Rev Inst Nal Enf Resp Mex 2003; 16: 70-73.

  12. Wang NS. The performed stomas connecting the pleural cavity and the lymphatic is the parietal pleura. Am Rev Respir Dis 1975; 111: 12-20.

  13. Ibarra-Perez C. Pleurodesis en derrame pleural maligno. Rev Inst Nal Enf Respir Mex 2006; 18; 123-131.

  14. Assi Z, Caruso JL, Herndon J, Patz EF. Cytologically proved malignant pleural effusions: distribution of transudates and exudates. Chest 1998: 1302-1304.

  15. Meyer PC. Metastasic carcinoma of the pleura. Thorax 1966; 21: 437-43.

  16. Sahn SA. Malignant pleural effusions. In: Fishman’s AP. Pulmonary diseases and disorders. Third edition. McGraw-Hill. 1997: 1429-1438.

  17. Auerbach R. Patterns of tumor metastasis: Organ selectivity in the spread of cancer cells. Lab Invest 1988; 58: 361-4.

  18. Sahn SA. Malignant pleural effusions. Clin Chest Med 1985; 6: 113-125.

  19. Light RW, MacGregor IM, Luchsinger PC, Ball WC. Pleural effusions: The diagnostic separation of transudates and exudates. Ann Intern Med 1972; 77: 507-13.

  20. Prakash UBS, Reinman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion. Mayo Clin Proc 1985; 60: 158-164.

  21. Chakrabarti B, Ryland I, Sheard J, Wraburton CJ, Earis JE. The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions. Chest 2006; 129: 1549-1555.

  22. Rodríguez-Panadero F, López-Mejías L. Survival time of patients with pleural metastasic predicted by glucose and pH studies. Chest 1989; 139: 663-7.

  23. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest 2000; 117: 79-86.

  24. Heffner JE, Heffner JN, Brown LK. Multilevel and continuous pleural fluid pH likelihood ratios for evaluating malignant pleural effusions. Chest 2003; 123: 1887-1894.

  25. Antunes G, Neville E, Duffy J, Ali N. On belhaf of the BTS pleural disease group, a subgroup of the BTS standards of care committee. Thorax 2003; 58(Suppl II): ii29-ii38.

  26. Rodríguez-Panadero F, Antony VB. Pleurodesis: State of the Art. Eur Respir J 1997; 10: 1648-1654.

  27. Aelony Y, King RR, Boutin Ch. Thoracoscopic talc poudrage in malignant pleural effusions. Effective pleurodesis despite pleural pH. Chest 1998; 113: 1007-12.

  28. Rodríguez-Panadero F, López-Mejías J. Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989; 139: 663-667.

  29. Rodríguez-Panadero F, Sánchez Gil R, Martín Juan J, Castillo Gómez J. Prediction of results of talc pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 1994; 149: A1103.

  30. Wallach HW. Intrapleural tetracycline for malignant pleural effusions. Chest 1975; 68: 510-2.

  31. Kitamura S, Sugiyama Y, Izumi T, Haysd R, Kosaka K. Intrapleural doxycycline for control of malignant pleural effusion. Curr Ther Res 1981; 30: 515-21.

  32. Light RW, Sasoon CS, Gruer SE, Despars JA, Wang NS. Comparison of efectiveness of tetracycline and minocycline in rabits. Am Rev Respir Dis 1992; 145: A868.

  33. Paladine W, Cunningham TJ, Sponzo R, Donavan M, Olson K, Horton J. Intracavitary bleomycin in the management of malignant effusions. Cancer 1976; 38: 1903-8.

  34. Fentiman IS, Rubens RD, Hayward JL. A comparison of intracavitary talc and tetracycline for the control of pleural effusion secondary to breast cancer. Eur J Cancer Clin Oncol 1986; 22: 1079.

  35. Kennedy L, Rusch VW, Strange C. Pleurodesis using talc slurry. Chest 1994; 106: 342.

  36. Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127: 909-915.

  37. Diacon AH, Wyser C, Bolliger CT, Tamm M, Pless M, Perruchoud AP, Soler M. Prospective randomized comparison of thoracoscopic talc poudrage Ander local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 2000; 162: 1445-1449.

  38. Dresler CM, Olak J, Herdon JE, Richards WG, Scalzatti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127: 909-915.

  39. Ren S, Terman DS, Bohach G, Silvers A, Hansen C, Colt H, Sahn SA. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest 2004; 126: 1529-1539.

  40. Vargas FS, Teixeira LR, Antonangelo L, Vaz MAC, Carmo AO, Marchi E, Light RW. Experimental pleurodesis in rabbits induced by silver nitrate or talc. 1-Year follow-up. Chest 2001; 119: 1516-1520.

  41. da Silveira M, Vargas FS, Marchi E, Rodriguez J, Jatene FB, Antonangelo L, Light RW. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 2005: 684-689.

  42. Marchi E, Vargas FS, Texeira LR, Acencio MMP, Antonangelo L, Light RW. Intrapleural low-dose silver nitrate elicits more pleural inflammation ans less systemic inflammation than low-dose talc. Chest 2005; 128: 1798-1804.

  43. Martinez-Moragon E, Aparicio J, Rogado MC, Sanchis J, Sanchis F, Gil-Suay V. Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J 1997: 2380-2383.

  44. Patz Jr EF, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Gilkeson RC, Herndon J. Sclerotherapy for malignant pleural effusion: a prospective randomized trail of bleomycin vs doxycycline with small-bore catheter drainage. Chest 1998; 113: 1305-1311.

  45. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117: 73-78.




2020     |     www.medigraphic.com